Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Short Interest Update

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) was the target of a significant decrease in short interest in the month of February. As of February 28th, there was short interest totalling 289,400 shares, a decrease of 18.0% from the February 13th total of 353,000 shares. Currently, 1.3% of the shares of the stock are short sold. Based on an average daily volume of 263,000 shares, the days-to-cover ratio is presently 1.1 days.

Eton Pharmaceuticals Stock Performance

NASDAQ ETON traded up $0.20 on Wednesday, reaching $14.88. The company’s stock had a trading volume of 243,011 shares, compared to its average volume of 158,113. Eton Pharmaceuticals has a twelve month low of $3.03 and a twelve month high of $18.41. The stock has a market cap of $387.64 million, a PE ratio of -67.64 and a beta of 1.37. The firm’s 50 day moving average is $15.45 and its two-hundred day moving average is $11.42.

Eton Pharmaceuticals (NASDAQ:ETON) last issued its quarterly earnings results on Tuesday, March 18th. The company reported ($0.02) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.02). Eton Pharmaceuticals had a negative net margin of 15.81% and a negative return on equity of 36.29%. The company had revenue of $11.65 million during the quarter, compared to the consensus estimate of $10.53 million. Equities research analysts anticipate that Eton Pharmaceuticals will post -0.14 EPS for the current fiscal year.

Institutional Trading of Eton Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. Tower Research Capital LLC TRC acquired a new stake in Eton Pharmaceuticals during the 4th quarter worth about $86,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Eton Pharmaceuticals during the 3rd quarter worth about $54,000. Jefferies Financial Group Inc. acquired a new stake in Eton Pharmaceuticals during the 4th quarter worth about $133,000. Raymond James Financial Inc. acquired a new stake in Eton Pharmaceuticals during the 4th quarter worth about $147,000. Finally, Bank of America Corp DE raised its holdings in Eton Pharmaceuticals by 5,422.4% during the 4th quarter. Bank of America Corp DE now owns 11,100 shares of the company’s stock worth $148,000 after buying an additional 10,899 shares during the period. Institutional investors and hedge funds own 27.86% of the company’s stock.

Analysts Set New Price Targets

ETON has been the subject of several research analyst reports. B. Riley reaffirmed a “buy” rating and issued a $24.00 price objective (up previously from $21.00) on shares of Eton Pharmaceuticals in a report on Wednesday. Craig Hallum upped their price target on shares of Eton Pharmaceuticals from $23.00 to $26.00 and gave the company a “buy” rating in a report on Wednesday. Finally, HC Wainwright reissued a “buy” rating and issued a $33.00 price target on shares of Eton Pharmaceuticals in a report on Wednesday.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.